On November 13, 2024, BioNTech SE signed an agreement to acquire Biotheus, a biotechnology company focused on antibody development for cancer and inflammatory diseases. This strategic move aims to enhance BioNTech's oncology initiatives.
AI Assistant
BIONTECH SE
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.